Literature DB >> 33224807

Clinical value of CTLA4 combined with clinicopathological factors in evaluating the prognosis of breast cancer.

Junyi Wu1, Lei Li2, Jiayi Chen2, Yuan Liu2, Junming Xu2, Zhihai Peng1.   

Abstract

BACKGROUND: Clinical prediction of breast cancer prognosis relies on both clinical-pathological features and biological markers. Many studies have revealed that tumor cytotoxic T lymphocyte antigen 4 (CTLA4) expression may present prognostic predicting value in cancers. We intended to explore the prognostic value of significant clinicopathological parameters and CTLA4 for predicting survival of patients with breast cancer.
METHODS: A total of 229 breast cancer patients who had radical surgery treatment between Sep 2009 and April 2011 were enrolled in this study. Immunohistochemical staining was performed to evaluate CTLA4 grade and Ki-67 index in breast cancer tissue. Univariate and multivariate logistic analysis, Kaplan-Meier survival analysis and ROC curve were used to explore the association between CTLA4 or clinicopathological parameters and disease-free survival (DFS). A nomogram was constructed based on the regression model to predict DFS of patients with breast cancer.
RESULTS: CTLA4 grade (OR 1.730, 95% CI: 1.213-2.468, P=0.002), Ki-67 (OR 1.449, 95% CI: 1.069-1.964, P=0.017) and N stage (lymph node metastasis) (OR 2.268, 95% CI: 1.588-3.303, P=0.000) showed significantly association with DFS of breast cancer patients. All these factors were independent predictors for poor survival, as patients with stage N2-3 tumors, high CTLA4 grade and Ki-67 index showed low survival probability (P<0.01). The conjunction of these factors exhibited good discrimination value (AUC 0.815, 95% CI: 0.749-0.882, P=0.000). Nomogram performed based on CTLA4 grade, Ki-67 index and N stage provided an efficient method to predict DFS of patients with breast cancer.
CONCLUSIONS: The high expression of CTLA4 and Ki-67 together with lymph node metastasis in breast cancer are independent risk factors that affect the prognosis of breast cancer patients. They have the potentiality to be utilized conjunctively as predictor in clinical practice. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Breast cancer; Ki-67 index; N stage; cytotoxic T lymphocyte antigen 4 (CTLA4); nomogram

Year:  2020        PMID: 33224807      PMCID: PMC7667109          DOI: 10.21037/gs-20-359

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  34 in total

1.  Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.

Authors:  Lina Liu; Yuhua Wang; Lei Miao; Qi Liu; Sara Musetti; Jun Li; Leaf Huang
Journal:  Mol Ther       Date:  2017-12-05       Impact factor: 11.454

Review 2.  Immunotherapy of Breast Cancer.

Authors:  Carmen Criscitiello; Giuseppe Curigliano
Journal:  Prog Tumor Res       Date:  2015-09-04

3.  Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.

Authors:  Martin R Weiser; Mithat Gönen; Joanne F Chou; Michael W Kattan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

4.  Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

Authors:  Anna Ehinger; Per Malmström; Pär-Ola Bendahl; Christopher W Elston; Anna-Karin Falck; Carina Forsare; Dorthe Grabau; Lisa Rydén; Olle Stål; Mårten Fernö
Journal:  Acta Oncol       Date:  2016-10-20       Impact factor: 4.089

5.  Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer.

Authors:  Gaochen Lan; Jie Li; Qiaomei Wen; Lin Lin; Libin Chen; Liyu Chen; Xi Chen
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 6.  The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Wolf-Herman Fridman; Jérôme Galon
Journal:  Semin Immunopathol       Date:  2011-04-05       Impact factor: 9.623

7.  Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.

Authors:  Annemieke Witteveen; Ingrid M H Vliegen; Gabe S Sonke; Joost M Klaase; Maarten J IJzerman; Sabine Siesling
Journal:  Breast Cancer Res Treat       Date:  2015-07-11       Impact factor: 4.872

8.  Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.

Authors:  Jianfei Fu; Lunpo Wu; Mengjie Jiang; Dan Li; Ting Jiang; Zhongwu Hong; Fan Wang; Shuguang Li
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

9.  Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer.

Authors:  Wei Sun; Yi-Zhou Jiang; Yi-Rong Liu; Ding Ma; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2016-04-12

10.  CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis.

Authors:  Zhiming Dai; Tian Tian; Meng Wang; Xinghan Liu; Shuai Lin; Pengtao Yang; Kang Liu; Yi Zheng; Peng Xu; Meng Liu; Xuewen Yang; Zhijun Dai
Journal:  PeerJ       Date:  2017-01-10       Impact factor: 2.984

View more
  1 in total

1.  Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes.

Authors:  Qiang Chen; Jiakang Ma; Xiaoyi Wang; Xiangqing Zhu
Journal:  Aging (Albany NY)       Date:  2022-06-07       Impact factor: 5.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.